RM-MET / Metabolic and incretin signalling
Amycretin
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Amycretin is a single investigational molecule designed to engage both GLP-1 and amylin receptors. Oral and subcutaneous programs must not be merged as if route and formulation were irrelevant.
Evidence position
Published randomized early clinical studies support Grade B, with clear human evidence but no approved finished-product comparator.
What the record does not establish
The trial record does not authenticate a market sample, reproduce a proprietary formulation, or show equivalence between routes.
Sources
- 01Oral amycretin first-in-human randomized trialPubMed
- Shows
- Phase 1 oral safety, pharmacokinetic and exploratory human outcome data
- Does not show
- Early-stage sponsor-funded study; not evidence about a separately sourced material
- 02Subcutaneous amycretin phase 1b/2a randomized trialPubMed
- Shows
- Human randomized evidence for the subcutaneous development formulation
- Does not show
- Study-specific formulation and early-phase design limit generalization
- 03Oral amycretin registry recordClinicalTrials.gov
- Shows
- Official study identity, route, design and status
- Does not show
- Registration does not establish approval or lot quality
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.Lancet (London, England) / 2025 Jul 12PMID 40550231 / DOI 10.1016/S0140-6736(25)01185-7
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews / 2026 Mar 11PMID 41054801 / DOI 10.1210/endrev/bnaf036
- Beyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology / 2026 AugPMID 42208956 / DOI 10.1016/S2213-8587(26)00100-2
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides / 2025 MayPMID 40081498 / DOI 10.1016/j.peptides.2025.171380
- Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.Cureus / 2025 MarPMID 40206909 / DOI 10.7759/cureus.80321
CLINICALTRIALS.GOV / FOUND RECORDS
- A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityCOMPLETED / PHASE1 / Novo Nordisk A/SNCT06049329 / DIRECT title MATCH: Amycretin